ADCT Earnings & Financial Statements
ADC Therapeutics S.A.
$1.45
-$0.25(-14.71%)
55
Overall
40
Value
75
Tech
52
Quality
Market Cap
$185.12M
Volume
1.74M
52W Range
$0.78 - $4.98
Target Price
$3.33
ADCT earnings and financial statements: ADC Therapeutics S.A.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ADCT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $81.36M | $70.84M | $69.56M | $209.91M | $33.92M |
| Cost of revenue | $5.80M | $5.95M | $2.53M | $3.30M | $1.39M |
| Operating income | -$121.50M | -$130.65M | -$165.99M | -$123.34M | -$261.72M |
| EBITDA | -$57.15M | -$75.07M | -$132.15M | -$105.58M | -$251.38M |
| Net income | -$142.62M | -$157.85M | -$240.05M | -$157.13M | -$230.03M |
| EPS (diluted) | $-1.12 | $-1.62 | $-2.94 | $-1.99 | $-3.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $323.15M | $321.98M | $354.78M | $490.86M | $617.97M |
| Total liabilities | $508.98M | $524.62M | $503.03M | $411.41M | $451.88M |
| Shareholders’ equity | -$185.83M | -$202.64M | -$148.25M | $79.45M | $154.03M |
| Cash and equivalents | $261.34M | $250.87M | $278.60M | $326.44M | $507.78M |
| Long-term debt | $113.49M | $121.63M | $122.88M | $116.26M | $6.99M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$141.17M | -$123.83M | -$118.69M | -$138.31M | -$233.38M |
| Capital expenditure | -$264.0K | -$867.0K | -$3.22M | -$687.0K | -$6.38M |
| Free cash flow | -$141.44M | -$124.70M | -$121.90M | -$139.00M | -$239.75M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ADCT | $1.45 | -14.7% | 1.74M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |